Amphetamine - PsychonautWiki


(Redirected from Adderall)
Summary sheet: Amphetamine
Chemical Nomenclature
Common names Amphetamine, Speed, Adderall, Pep
Substitutive name α-Methylphenethylamine
Systematic name (RS)-1-Phenylpropan-2-amine
Class Membership
Psychoactive class Stimulant
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Bioavailability 75%+[1]
Threshold 5 mg
Light 7.5 - 20 mg
Common 20 - 40 mg
Strong 40 - 70 mg
Heavy 70 mg +
Total 6 - 8 hours
Onset 30 - 45 minutes
Come up 30 - 135 minutes
Peak 2.5 - 4 hours
Offset 2 - 3 hours
After effects 3 - 6 hours

Threshold 4 mg
Light 6 - 15 mg
Common 15 - 30 mg
Strong 30 - 50 mg
Heavy 50 mg +
Total 3 - 6 hours
Onset 1 - 5 minutes
Come up 30 - 90 minutes
Peak 1 - 2 hours
Offset 1.5 - 3 hours
After effects 2 - 4 hours

Threshold 4 mg
Light 6 - 15 mg
Common 15 - 30 mg
Strong 30 - 50 mg
Heavy 50 mg +
Total 3 - 6 hours
Onset 2 - 10 seconds
Come up 2 - 10 seconds
Peak 2 - 4 hours
Offset 1 - 2 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


Amphetamine (also known as alpha-methylphenethylamine, amfetamine, and speed) is a classical stimulant substance of the phenethylamine class. It is considered to be the prototypical stimulant due to its extensive history of research and clinical use. It produces its effects by promoting the release of the neurotransmitters dopamine and norepinephrine in the brain.[2]

Amphetamine was first synthesized in 1887, but its psychostimulant effects were not discovered until 1929.[3] In the 1930s, it was sold over-the-counter under the name "Benzedrine" and widely used to treat a range of ailments such as alcohol hangover, narcolepsy, depression, and weight reduction.[4] Due to issues with addiction and abuse, it was eventually listed as a controlled substance under the United Nations 1971 "Convention on Psychotropic Substances".[5]

Amphetamine is now primarily a prescription drug used to treat attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity.[6][7] Additionally, it sees widespread illicit use as a performance enhancing agent and recreational substance.

Subjective effects include stimulation, focus enhancement, motivation enhancement, increased libido, appetite suppression, and euphoria. It is usually taken orally, but can also be insufflated, injected, or administered rectally. Lower doses tend to increase focus and productivity while higher doses tend to increase sociability, sexual desire, and euphoria.

Amphetamine has high abuse potential. Chronic use (i.e. high dose, repeat administration) is associated with compulsive redosing, escalating tolerance, and psychological dependence. Additionally, abuse has been linked to a number of health conditions, especially cardiovascular issues such as high blood pressure and increased risk of stroke.[8]

It is highly advised to use harm reduction practices if using this substance.

History and culture

Amphetamine was first synthesized in Germany in 1887 by the Romanian chemist Lazăr Edeleanu, who named it phenylisopropylamine.[9] However, its stimulant effects remained unknown until 1927, when it was independently re-synthesized by Gordon Alles and discovered to have sympathomimetic properties.[10]

In late 1933, Smith, Kline and French began selling amphetamine in the form of a decongestant inhaler under the name Benzedrine.[11] Benzedrine sulfate was introduced 3 years later and was used to treat a wide variety of medical conditions, including narcolepsy, obesity, low blood pressure, low libido, and chronic pain.[12]

During World War II, amphetamine and methamphetamine were used extensively by both the Allied and Axis forces for their stimulant and performance-enhancing effects.[13][14] As its addictive properties became known, governments began to place strict controls on its sale.[15]

Amphetamine is still illegally synthesized and sold on the black market, primarily in European countries.[16] Among European Union (EU) member states, 1.2 million young adults used illicit amphetamine or methamphetamine in 2013. During 2012, approximately 5.9 metric tons of illicit amphetamine were seized within EU member states;[16] the "street price" of illicit amphetamine within the EU ranged from €6–38 per gram during the same period.[16]

Outside Europe, the illicit market for amphetamine is much smaller than the market for methamphetamine and MDMA.[16]


Amphetamine, also known as alpha-methylphenethylamine, is a synthetic substance of the phenethylamine family. The chemical structure of amphetamine consists of phenethylamine, a phenyl ring bound to an amino (NH2) group through an ethyl chain, with an additional methyl substitution at Rα. The name 'amphetamine' is a contraction from αlphamethylphenethylamine

Amphetamine is the parent compound of the substituted amphetamines, a highly diverse group that includes such substances as bupropion, phenmetrazine, methamphetamine, MDMA, and the DOx series.

At room temperature, the pure freebase is a mobile, colorless, and volatile liquid with a characteristically strong amine odor, and acrid, burning taste.[17]


Amphetamine is a chiral compound. Racemic amphetamine (dl-amphetamine) contains two optical isomers, or enantiomers:

  • l-amphetamine (l-amph, l-AMP), levamfetamine (INN), levoamphetamine, levorotatory amphetamine, l-isomer amphetamine, (R)-(−)-amphetamine, (R)-amphetamine, (−)-amphetamine, or (2R)-1-Phenylpropan-2-amine (IUPAC name), is the 'left-handed' enantiomer form of amphetamine.
  • d-amphetamine (d-amph, d-AMP), dexamphetamine (INN), dextroamphetamine, dextrorotatory amphetamine, d-isomer amphetamine, or (S)-(+)-amphetamine, (S)-amphetamine, (+)-amphetamine, (2S)-1-phenylpropan-2-amine (IUPAC name), or "Dexedrine" (trade name amongst others), is the 'right-handed' enantiomer form of amphetamine.

Adderall and many other formulations of mixed amphetamine salts contain the enantiomers in a 3:1 ratio of d to l. This is achieved by mixing one part racemic amphetamine and one part d-amphetamine.


Amphetamine exerts its behavioural effects by increasing the signaling activity of neurotransmitters norepinephrine and dopamine in the reward and executive function pathways of the brain. The reinforcing and motivational effects of amphetamine are mostly due to enhanced dopaminergic activity in the mesolimbic pathway.[18]

The euphoric and locomotor-stimulating effects of amphetamine are dependent upon the magnitude and speed by which it increases synaptic dopamine and norepinephrine concentrations in the striatum.[19]

Amphetamine is a potent full agonist of the trace amine-associated receptor 1 (TAAR1) and interacts with vesicular monoamine transporter 2 (VMAT2).[20][21][22] Combined action on TAAR1 and VMAT2 results in increased concentrations of dopamine and norepinephrine in the synapses, which stimulates neuronal activity.

Dextroamphetamine is a more potent agonist of TAAR1 than levoamphetamine.[23] Consequently, dextroamphetamine produces greater CNS stimulation than levoamphetamine, roughly three to four times more, but levoamphetamine has slightly stronger cardiovascular and peripheral effects.[24][25]

The exact bioavailability of amphetamine is not known, but it is believed to be over 75% by mouth, and higher by injection or intranasal administration[26][27]. Its absorption and excretion may be pH dependent. The basic form is more readily absorbed in the intestine and less readily removed by the kidneys, potentially increasing its half life [27]. It is removed excreted by the kidneys and only a small amount by hepatic enzymes.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

After effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

This radar plot shows therelative physical harm, social harm, and dependence of amphetamine.[34]

As of March 2014, there is no evidence that amphetamine is directly neurotoxic in humans.[35] However, high-dose amphetamine can cause indirect neurotoxicity as a result of increased oxidative stress from reactive oxygen species and autoxidation of dopamine.[36][37][38]

In rodents and primates, sufficiently high doses of amphetamine causes damage to dopamine neurons, characterized as reduced transporter and receptor function.[39] Animal models of neurotoxicity from high-dose amphetamine exposure indicate that the occurrence of hyperpyrexia (i.e., core body temperature ≥ 40 °C) is necessary for the development of amphetamine-induced neurotoxicity. [40]

Melatonin has been shown to prevent (if used 30min+ before dosing) and reverse amphetamine induced neurotoxicity of TH-pSer40 and calpastatin levels in the Substantia Nigra of rats.[41][42]

It is strongly recommended that one use harm reduction practices when using this substance.

Lethal dosage

The LD50 (the dosage required to kill 50% of the test subjects) of amphetamine in rats has been found to be between roughly 15 mg and 180 mg per kilogram, depending on the study.[43] No formal studies in humans have been carried out and the exact toxic dosage is unknown.

Dependence and abuse potential

Amphetamine has high abuse potential and can cause psychological dependence with chronic use.

When dependence has developed, cravings and withdrawal effects may occur if use is suddenly discontinued.[44][45] Withdrawal symptoms include paranoia, depression, dream potentiation, anxiety, itching, mood swings, irritability, fatigue, insomnia, an intense craving for more amphetamine or other stimulants.

Addiction is a serious risk with chronic or heavy recreational amphetamine use, but is unlikely to arise from typical medical use.[46][47][48]

Tolerance to many of the effects of amphetamine develops with prolonged and repeated use. This results in the user having to administer increasingly large doses to achieve the same effects. Upon single administration, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption).

Amphetamine exhibits cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of amphetamine most stimulants will have a reduced effect.


Main article: Stimulant psychosis

Severe amphetamine overdose can result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, delusions).[49] A review on treatment for amphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[49][50] The same review asserts that antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[49] Psychosis very rarely arises from therapeutic use.[51][52]

Dangerous interactions

Disclaimer: Psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous or even life-threatening when combined with other substances. The following list includes some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Alcohol - Drinking alcohol on stimulants is considered risky because it reduces the sedative effects of the alcohol that the body uses to gauge drunkenness. This often leads to excessive drinking with greatly reduced inhibitions, increasing the risk of liver damage and increased dehydration. The effects of stimulants will also allow one to drink past a point where they might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less.
  • GHB/GBL - Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the depressant effects of the GHB/GBL may overcome the user and cause respiratory arrest.
  • Opioids - Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
  • Cocaine - The rewarding effects of cocaine are mediated by DAT inhibition, and an increase of exocytosis of dopamine through the cell membrane. Amphetamine reverses the direction of DAT and the direction vesicular transports within the cell by a pH mediated mechanism of displacement, thus excludes the regular mechanism of dopamine release through means of exocytosis because the effects Na+/K+ ATPase are inhibited. You will find cardiac effects with the combination of cocaine and amphetamine due to a SERT mediated mechanism from the subsequent activation of 5-HT2B, which is an effect of serotonin-related valvulopathy. Amphetamines generally cause hypertension in models of abuse, and this combination can increase the chances of syncope due to turbulent blood flow during valve operation. The rewarding mechanisms of cocaine are reversed by administration of amphetamine. [53][54]
  • Cannabis - Stimulants increase anxiety levels and the risk of thought loops and paranoia which can lead to negative experiences.
  • Caffeine - This combination of stimulants is generally considered unnecessary and may increase strain on the heart, as well as potentially causing anxiety and physical discomfort.
  • Tramadol - Tramadol and stimulants both increase the risk of seizures.
  • DXM - Both substances raise heart rate, in extreme cases, panic attacks caused by these substances have led to more serious heart issues.
  • Ketamine - Combining amphetamine and ketamine may result in psychoses that resemble schizophrenia, but not worse than the psychoses produced by either substance alone, but this is debatable. This is due to amphetamines ability to attenuated the disruption of working memory caused by ketamine. Amphetamine alone may result in grandiosity, paranoia, or somatic delusions with little to no effect on negative symptoms. Ketamine, however, will result in thought disorders, disruption of executive functioning, and delusions due to a modification of conception. These mechanisms are due to an increase of dopaminergic activity in the mesolimbic pathway caused by amphetamine due to its pharmacology effecting dopamine, and due to a disruption of dopaminergic functioning in the mesocortical pathways via NMDA antagonism effects of ketamine. Combining the two, you may expect mainly thought disorder along with positive symptoms.[55]
  • PCP - Increases risk of tachycardia, hypertension, and manic states.
  • Methoxetamine - Increases risk of tachycardia, hypertension, and manic states.
  • Psychedelics (e.g. LSD, mescaline, psilocybin) - Increases risk of anxiety, paranoia, and thought loops.
    • 25x-NBOMe - Amphetamines and NBOMes both provide considerable stimulation that when combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
    • 2C-T-x - Suspected of mild MAOI properties. May increase the risk of hypertensive crisis.
    • 5-MeO-xxT - Suspected of mild MAOI properties. May increase the risk of hypertensive crisis.
    • DOx
  • aMT - aMT has MAOI properties which may interact unfavorably with amphetamines.
  • MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with amphetamine can lead to hypertensive crises.

Reagent results

Exposing compounds to the reagents gives a colour change which is indicative of the compound under test.

Marquis Mecke Mandelin Liebermann Froehde Robadope
Orange - red No reaction slow (dark) green Orange - red No reaction Pink
Ehrlich Hofmann Simon’s Scott Folin
No reaction No reaction No reaction No reaction Light orange

Legal status

Internationally, amphetamine is a Schedule II controlled substance under the United Nations 1971 Convention on Psychotropic Substances.[56]

  • Australia: Amphetamine is a Schedule 8 controlled substance.[57]
  • Austria: Amphetamine is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).[citation needed]
  • Brazil: Amphetamine is a Class A3 psychoactice substance.[citation needed]
  • Canada: Amphetamine is a Schedule I drug in Canada.[58]
  • Germany: Amphetamine was added to the Opiumgesetz (Opium Act) in 1941.[59] In accordance to the Narcotics Act reform of 1981, it is controlled under Anlage III BtMG (Narcotics Act, Schedule III).[60] It can only be prescribed on a narcotic prescription form.
  • Japan: Amphetamine is prohibited even for medical use in Japan.[61]
  • Luxembourg: Amphetamine is a prohibited substance for recreational use. [62]
  • The Netherlands: Amphetamine is a List I controlled substance.[63]
  • New Zealand: Amphetamine is a Class B controlled substance.[64]
  • South Korea: Amphetamine is prohibited even for medical use in South Korea.[citation needed]
  • Sweden: Amphetamine is classified as a drug by the United Nations and is included in list P II in the 1971 Psychotropic Convention, as well as in list II in Sweden.[65]
  • Switzerland: Amphetamine is a controlled substance specifically named under Verzeichnis A. Medicinal use is permitted.[66]
  • Thailand: Amphetamine is classified as a category 1 narcotic under the Thai Narcotic Act of 2012.[67]
  • United Kingdom: Amphetamine is a Class B drug in the United Kingdom.[68]
  • United States: Amphetamine is a Schedule II controlled substance in the United States.[69]

See also

External links


  • Galli, A., Poulsen, N.W., Sulzer, D., & Sonders, M.S. (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Progress in Neurobiology, 75 6, 406-33.
  • Berman, S. M., Kuczenski, R., McCracken, J. T., & London, E. D. (2009). Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 14(2), 123.
  • Baumann, M., Carroll, F.I., Dersch, C.M., Partilla, J.S., Rothman, R.B., Romero, D., & Rice, K. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39 1, 32-41. doi: 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3


  1. ""
  2. Kish, S. J. (2008). Pharmacologic mechanisms of crystal meth. Canadian Medical Association Journal, 178(13), 1679-1682.
  3. Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013). Amphetamine, past and present–a pharmacological and clinical perspective. Journal of Psychopharmacology, 27(6), 479-496.
  4. Angrist, B., & Sudilovsky, A. (1978). Central nervous system stimulants: historical aspects and clinical effects. In Stimulants (pp. 99-165). Springer, Boston, MA.
  6. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter? ( / NCBI) |
  7. Narcolepsy: current treatment options and future approaches |
  8. Westover AN, McBride S, Haley RW. Stroke in Young Adults Who Abuse Amphetamines or Cocaine: A Population-Based Study of Hospitalized Patients. Arch Gen Psychiatry. 2007;64(4):495–502. doi:10.1001/archpsyc.64.4.495
  9. Lazăr Edeleano: Über einige Derivate der Phenylmethacrylsäure und der Phenylisobuttersäure. In: Berichte der Deutschen chemischen Gesellschaft zu Berlin; 20. Jg. (1887), Band 3, S. 616–622.
  10. Sulzer D, Sonders MS, Poulsen NW, Galli A (April 2005). "Mechanisms of neurotransmitter release by amphetamines: a review". Prog. Neurobiol. 75 (6): 406–433. doi:10.1016/j.pneurobio.2005.04.003. PMID 15955613.
  11. Rasmussen N (July 2006). "Making the first anti-depressant: amphetamine in American medicine, 1929–1950". J. Hist. Med. Allied Sci. 61 (3): 288–323. PMID 16492800.
  12. Bett WR (August 1946). "Benzedrine sulphate in clinical medicine; a survey of the literature". Postgrad. Med. J. 22 (250): 205–218. doi:10.1136/pgmj.22.250.205. PMC 2478360  Freely accessible. PMID 20997404.
  13. Rasmussen N (2011). "Medical science and the military: the Allies' use of amphetamine during World War II". J. Interdiscip. Hist. 42 (2): 205–233. PMID 22073434.
  14. Defalque RJ, Wright AJ (April 2011). "Methamphetamine for Hitler's Germany: 1937 to 1945". Bull. Anesth. Hist. 29 (2): 21–4, 32. PMID 22849208.
  15. "Historical overview of methamphetamine". Vermont Department of Health. Government of Vermont. Archived from the original on 5 October 2012. Retrieved 29 January 2012.
  16. 16.0 16.1 16.2 16.3 Mohan J, ed. (June 2014). "World Drug Report 2014" (PDF). United Nations Office on Drugs and Crime. p. 3. Retrieved 18 August 2014.
  17. "Chemical and Physical Properties". Amphetamine. PubChem Compound. United States National Library of Medicine – National Center for Biotechnology Information. Retrieved 13 October 2013.
  18. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 13: Higher Cognitive Function and Behavioral Control". In Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York, USA: McGraw-Hill Medical. pp. 318, 321. ISBN 9780071481274.
  19. Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). "Amphetamine, past and present – a pharmacological and clinical perspective". J. Psychopharmacol. 27 (6): 479–496. doi:10.1177/0269881113482532. PMC 3666194 Freely accessible. PMID 23539642.
  20. The Emerging Role of Trace Amine Associated Receptor 1 in the Functional Regulation of Monoamine Transporters and Dopaminergic Activity ( / NCBI) |
  21. Drug banks amphetamine targets |
  22. TA1 receptor |
  23. Lewin AH, Miller GM, Gilmour B (December 2011). "Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class". Bioorg. Med. Chem. 19 (23): 7044–7048. doi:10.1016/j.bmc.2011.10.007. PMC 3236098 Freely accessible. PMID 22037049.
  24. Westfall DP, Westfall TC (2010). "Miscellaneous Sympathomimetic Agonists". In Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman's Pharmacological Basis of Therapeutics (12th ed.). New York, USA: McGraw-Hill. ISBN 9780071624428.
  25. Eiden LE, Weihe E (January 2011). "VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse". Ann. N. Y. Acad. Sci. 1216: 86–98. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197 Freely accessible. PMID 21272013.
  26. [1]
  27. 27.0 27.1 [2]
  28. Adult ADHD Medications and Their Cardiovascular Implications |
  29. Adult ADHD Medications and Their Cardiovascular Implications |
  30. Adult ADHD Medications and Their Cardiovascular Implications |
  31. Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with d-Amphetamine in Healthy Subjects |
  32. Stimulants for the Control of Hedonic Appetite |
  33. Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with d-Amphetamine in Healthy Subjects |
  34. Development of a rational scale to assess the harm of d rugs of potential misuse (ScienceDirect) |
  35. Human health effects - Amphetamine |
  36. Malenka RC, Nestler EJ, Hyman SE (2009). "15". In Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 370. ISBN 9780071481274. "Unlike cocaine and amphetamine, methamphetamine is directly toxic to midbrain dopamine neurons."
  37. Toxicity of amphetamines: an update |
  38. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. ( / NCBI) |
  39. Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD |
  40. Bowyer JF, Hanig JP (November 2014). "Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity". Temperature (Austin). 1 (3): 172–182. "Hyperthermia alone does not produce amphetamine-like neurotoxicity but AMPH and METH exposures that do not produce hyperthermia (≥40°C) are minimally neurotoxic. Hyperthermia likely enhances AMPH and METH neurotoxicity directly through disruption of protein function, ion channels and enhanced ROS production. ... The hyperthermia and the hypertension produced by high doses amphetamines are a primary cause of transient breakdowns in the blood-brain barrier (BBB) resulting in concomitant regional neurodegeneration and neuroinflammation in laboratory animals. ... In animal models that evaluate the neurotoxicity of AMPH and METH, it is quite clear that hyperthermia is one of the essential components necessary for the production of histological signs of dopamine terminal damage and neurodegeneration in cortex, striatum, thalamus and hippocampus." |
  41. Role of Melatonin in Reducing Amphetamine-Induced Degeneration in Substantia Nigra of Rats via Calpain and Calpastatin Interaction |
  42. Neuroprotective effects of melatonin on amphetamine-induced dopaminergic fiber degeneration in the hippocampus of postnatal rats. |
  43. Amphetamine - human health effects |
  44. "Amphetamines: Drug Use and Abuse" |
  45. Pérez‐Mañá, C., Castells, X., Torrens, M., Capellà, D., & Farre, M. (2013). Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database of Systematic Reviews, (9). DOI: 10.1002/14651858.CD009695.pub2
  46. "Adderall XR Prescribing Information" |
  47. Stolerman IP (2010). Stolerman IP, ed. Encyclopedia of Psychopharmacology. Berlin; London: Springer. p. 78. ISBN 9783540686989.
  48. "Miscellaneous Sympathomimetic Agonists" |
  49. 49.0 49.1 49.2 Shoptaw, S. J., Kao, U., & Ling, W. (2009). Treatment for amphetamine psychosis. The Cochrane database of systematic reviews, (1), CD003026-CD003026.
  50. Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  51. Stimulant Misuse: Strategies to Manage a Growing Problem |
  53. Sustained Release d-Amphetamine Reduces Cocaine but not Speedball-Seeking in Buprenorphine-Maintained Volunteers
  54. {{#1:Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation-compressed SMALL.pdf}}
  55. Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine
  56. "CONVENTION ON PSYCHOTROPIC SUBSTANCES 1971" (PDF). United Nations. Retrieved December 19, 2019. 
  57. "POISONS STANDARD DECEMBER 2019". Office of Parliamentary Counsel. Retrieved December 19, 2019. 
  58. Controlled Drugs and Substances Act |
  59. "Sechste Verordnung über die Unterstellung weiterer Stoffe unter die Bestimmungen des Opiumgesetzes" (in German). Reichsministerium des Innern. Retrieved December 25, 2019. 
  60. "Anlage III BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 19, 2019. 
  61. The problem of the abuse of amphetamines in Japan |
  62. Règlement grand-ducal du 20 mars 1974 concernant certaines substances psychotropes |
  63. "Opiumwet" (in Dutch). Ministerie van Binnenlandse Zaken en Koninkrijksrelaties. Retrieved December 19, 2019. 
  64. "Schedule 2 - Class B controlled drugs". Parliamentary Counsel Office. Retrieved December 19, 2019. 
  65. Läkemedelsverkets föreskrifter (LVFS 1997:12) om förteckningar över narkotika, konsoliderad version till och med LVFS 2010:1
  66. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  67. Thai Narcotic Act of 2012 |
  68. Misuse of Drugs Act of 1971 |
  69. Controlled Drugs and Substances Act |